QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Drug–Drug Interactions and Pharmacovigilance

Test your understanding of the concepts covered by Drug–Drug Interactions and Pharmacovigilance: Recognising, Assessing and Characterising Safety Risks.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should the underlying disease and comorbidities be considered in a suspected interaction case?

They are irrelevant once a known interaction exists They may provide realistic alternative explanations or modify exposure and susceptibility They determine whether the case is reportable regardless of the event They replace the need to assess medicine exposure

Question 2 of 10 Which potential regulatory measure may be appropriate when an interaction is sufficiently supported and clinically important?

Automatically withdraw both medicines from the market Consider contraindications, warnings, dosing recommendations, monitoring or other risk-minimisation measures Delete the interaction from individual case reports to avoid duplication Publish the interaction only in an internal database without considering product information

Question 3 of 10 Why can repeated reports involving the same commonly co-prescribed medicines be difficult to interpret?

Common combinations cannot cause interactions Frequent co-prescribing creates many opportunities for coincidental associations and confounding by indication Repeated reports automatically represent duplicate cases Common medicines are excluded from disproportionality analyses

Question 4 of 10 A patient develops excessive anticoagulation while receiving two medicines, one of which is known to inhibit metabolism of the other. Which additional information would most strengthen the interaction assessment?

Confirmation that the medicines were prescribed by different physicians A compatible time course, objective coagulation results and assessment of competing causes The fact that the patient had previously used both medicines without an event A statement that the event was serious, without clinical details

Question 5 of 10 A case report states that an interaction was considered 'possible,' but no dose information or reliable treatment dates are available. How should the medical review document the conclusion?

Upgrade the interaction to confirmed because the mechanism is theoretically possible Document the hypothesis and retain the uncertainty, potentially requesting follow-up Ignore the interaction because incomplete information excludes it Classify the case as a validated signal

Question 6 of 10 Which sequence best represents the layered assessment of a suspected drug–drug interaction in an individual case?

Concomitant exposure, plausible mechanism, relevant change in exposure or effect, compatible event, contribution assessment Adverse event, disproportionality, regulatory action, exposure confirmation, mechanism Product identification, confirmed causality, dose reduction, signal validation, case closure Mechanistic theory, product labelling, case count, incidence calculation, benefit–risk conclusion

Question 7 of 10 Why should a deliberate rechallenge generally not be treated as a routine pharmacovigilance test of an interaction?

Rechallenge can never provide useful evidence Rechallenge is generally a clinical decision and may expose the patient to avoidable risk Rechallenge is required before any interaction can be documented Rechallenge only applies to pharmacokinetic interactions

Question 8 of 10 Which governance capability would best demonstrate control of interaction surveillance during an inspection?

A list of all theoretically possible interactions, without case or decision records Traceability from recognition and medical assessment through coding, follow-up, signal review and escalation decisions Evidence that every reported interaction was classified as confirmed A prescribing database maintained independently of pharmacovigilance processes

Question 9 of 10 Which exposure information would be most useful when evaluating whether a suspected interaction was clinically relevant?

Only the trade names of the two medicines Dose, dosing interval, duration, adherence, formulation, route and treatment changes Only the date on which the adverse event was reported The medicine's marketing authorisation date

Question 10 of 10 Which situation most clearly illustrates a pharmacodynamic interaction rather than a pharmacokinetic interaction?

An enzyme inhibitor increases the plasma concentration of a substrate A transporter inducer reduces absorption of an oral medicine Two medicines independently lower blood pressure and together cause symptomatic hypotension Renal tubular competition reduces elimination of one medicine

QPPV.com

Knowledge Assessment: Drug–Drug Interactions and Pharmacovigilance

Cookie Settings